Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:1578-88.

Slides:

Advertisements

Similar presentations

Sibbing D, et al. J Am Coll Cardiol 2009;53:

Advertisements

Ware, L. B. et al. N Engl J Med 2005;353: Physiology of Microvascular Fluid Exchange in the Lung.

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Philip J. Barter, et al. Circulation 2011;124:

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355: Steven E. Kahn,

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:

Baseline Characteristics of Patients Referred for Stress Myocardial Perfusion Testing by Erectile Function Classification James K. Min, et al, Arch Intern.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Christopher P. Cannon, M. D. , Eugene Braunwald, M. D. , Carolyn H

The SPRINT Research Group

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

Baseline Characteristics of the Patients Part I

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

TNT: Baseline and final LDL cholesterol levels

PAD Patients vs Post-ACS Patients:

Baseline characteristics of patients

TNT Study: Baseline Characteristics of the Patients

PREMIER: Rate of hypertension at 18 months

Trial profile John A Dormandy et al. Lancet 2005;366:

Study Design Ketil Lunde, et al. N Engl J Med 2006;355:

Fellström BC, et al. N Engl J Med 2009;360:1455-7

A: Kaplan-Meier estimate of time to first LLA

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Enrollment and Outcomes

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Baseline Characteristics of the Subjects

Characteristics of the Patients at Baseline*

A.V. Khera et al. N Engl J Med 2011;364:127-35

Baseline Characteristics of the Study Participants

Baseline Characteristics, Blood Pressures, and Laboratory Values

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Effects of Pay-for-Performance on the Quality of Primary Care in England Mean Scores for Clinical Quality at the Practice Level for Aspects of Care for.

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Collet JP, et al. Lancet 2009;373:309-17

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Effect of VKORC1 Haplotype Combination on Clinical Warfarin Dose - Common haplotypes (H1, H2, H7, H8, and H9) were clustered with use of the UPGMA method.

Baseline Characteristics of the Patients – Part I

RECORD Study: Enrollment and Outcomes

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Baseline Characteristics of the Patients - Part I

Enrollment and Outcomes

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Baseline characteristics of study population

Representative Light Micrographs of Kidney Sections Illustrating the Histologic Scoring Criteria Giuseppe Remuzzi, et al, N Engl J Med 2006;3354:

Demographic Characteristics of Patients Treated With Statins Versus Those Not Treated With Statins Goldberger JJ, et al. J Am Coll Cardiol 2006;48:

Flowchart of the process of study selection LAR indicates laboratory-defined aspirin resistance Jaapjan D. Snoep, et al. Arch Intern Med 2007;167:

• Kaplan-Meier analyses of (A) time-to-recurrence (TTR) for the subgroup of patients with high-risk melanoma who had relapsed (n=82), (B) recurrence-free.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Survival of subjects listed for heart transplantation with and without spirometry. Survival of subjects listed for heart transplantation with and without.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Overexpression of SUFU and GLI1 in the poor clinical outcome subgroup was confirmed by real-time PCR along with its association with disease progression.

Presentation transcript:

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:1578-88

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part II Kaare Harald Bønaa, et al. N Engl J Med 2006;354:1578-88

Plasma Levels of Total Homocysteine and B Vitamins at Baseline, after Two Months, and at the End of the Intervention Kaare Harald Bønaa, et al. N Engl J Med 2006;354:1578-88

Clinical Outcomes and Rate Ratios Kaare Harald Bønaa, et al. N Engl J Med 2006;354:1578-88

Kaplan-Meier Estimates of the Probability of Reaching the Primary End Point during Follow-up Kaare Harald Bønaa, et al. N Engl J Med 2006;354:1578-88

Rate Ratios for the Primary End Point in Various Subgroups Kaare Harald Bønaa, et al. N Engl J Med 2006;354:1578-88